Richard A. Michaelson

3.6k total citations · 1 hit paper
18 papers, 1.0k citations indexed

About

Richard A. Michaelson is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Richard A. Michaelson has authored 18 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Richard A. Michaelson's work include Cancer Treatment and Pharmacology (3 papers), Advanced Breast Cancer Therapies (2 papers) and Cancer, Lipids, and Metabolism (2 papers). Richard A. Michaelson is often cited by papers focused on Cancer Treatment and Pharmacology (3 papers), Advanced Breast Cancer Therapies (2 papers) and Cancer, Lipids, and Metabolism (2 papers). Richard A. Michaelson collaborates with scholars based in United States, France and Portugal. Richard A. Michaelson's co-authors include R. Borson, Lukas C. Amler, Charles L. Vogel, Yu-Waye Chu, Steven Limentani, Elizabeth Tan-Chiu, Howard A. Burris, Sandhya Girish, Hope S. Rugo and Ian E. Krop and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Richard A. Michaelson

18 papers receiving 988 citations

Hit Papers

Phase II Study of the Ant... 2010 2026 2015 2020 2010 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
    2010 568 citations Howard A. Burris, Hope S. Rugo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard A. Michaelson United States 9 833 389 196 168 125 18 1.0k
Tatsunori Shimoi Japan 16 775 0.9× 243 0.6× 422 2.2× 229 1.4× 176 1.4× 105 1.2k
Robert N. Raju United States 16 667 0.8× 181 0.5× 241 1.2× 284 1.7× 178 1.4× 30 985
Devika Gajria United States 12 536 0.6× 190 0.5× 136 0.7× 322 1.9× 123 1.0× 31 867
Rebecca Moroose United States 9 747 0.9× 217 0.6× 357 1.8× 191 1.1× 190 1.5× 23 1.0k
Hubert Orfeuvre France 15 806 1.0× 151 0.4× 173 0.9× 99 0.6× 281 2.2× 37 1.1k
Mayra Ramos Cuba 16 461 0.6× 268 0.7× 297 1.5× 180 1.1× 60 0.5× 33 827
Kaori Fujimoto-Ouchi United States 15 552 0.7× 241 0.6× 283 1.4× 242 1.4× 101 0.8× 28 823
Virpi Rantanen Finland 14 411 0.5× 109 0.3× 118 0.6× 283 1.7× 149 1.2× 33 736
M. Wolf Germany 20 801 1.0× 133 0.3× 342 1.7× 436 2.6× 85 0.7× 72 1.3k
Sylvie Assadourian France 18 912 1.1× 126 0.3× 588 3.0× 343 2.0× 227 1.8× 33 1.3k

Countries citing papers authored by Richard A. Michaelson

Since Specialization
Citations

This map shows the geographic impact of Richard A. Michaelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard A. Michaelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard A. Michaelson more than expected).

Fields of papers citing papers by Richard A. Michaelson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard A. Michaelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard A. Michaelson. The network helps show where Richard A. Michaelson may publish in the future.

Co-authorship network of co-authors of Richard A. Michaelson

This figure shows the co-authorship network connecting the top 25 collaborators of Richard A. Michaelson. A scholar is included among the top collaborators of Richard A. Michaelson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard A. Michaelson. Richard A. Michaelson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Ligibel, Jennifer A., Constance Cirrincione, Minetta C. Liu, et al.. (2015). Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). JNCI Journal of the National Cancer Institute. 107(9). 44 indexed citations
2.
Pacheco, Teresa R., Suhail M. Ali, Jonathan F. Lara, et al.. (2015). Activation of PI3K/AKT/mTOR pathway in ER+ breast cancer: Analysis of paired primary and metastatic tumor samples.. Journal of Clinical Oncology. 33(15_suppl). 577–577. 1 indexed citations
3.
Nadji, Mehrdad, Norman L. Block, Andrew V. Schally, et al.. (2015). GHRH-receptor as a new targetable biomarker in breast cancer and its correlation with ER/PR/HER2 status.. Journal of Clinical Oncology. 33(15_suppl). 576–576. 1 indexed citations
4.
Block, Norman L., Mehrdad Nadji, Andrew V. Schally, et al.. (2014). Expression of GHRH-R in primary and metastatic mammary carcinomas.. Journal of Clinical Oncology. 32(26_suppl). 19–19. 1 indexed citations
5.
Vacirca, Jeffrey, Michaela L. Tsai, Adam Brufsky, et al.. (2013). Initial results from the 21-gene breast cancer assay registry: A prospective observational study in patients (pts) with ER+, early-stage invasive breast cancer (EBC).. Journal of Clinical Oncology. 31(15_suppl). 565–565. 2 indexed citations
6.
Burris, Howard A., Hope S. Rugo, Svetislava J. Vukelja, et al.. (2010). Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy. Journal of Clinical Oncology. 29(4). 398–405. 568 indexed citations breakdown →
7.
Rincón, Mercedes, Gloria Broadwater, Lyndsay N. Harris, et al.. (2006). Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Research and Treatment. 100(3). 301–308. 22 indexed citations
8.
Winer, Eric P., Donald A. Berry, Susan Woolf, et al.. (2004). Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342. Journal of Clinical Oncology. 22(11). 2061–2068. 214 indexed citations
9.
Michaelson, Richard A., et al.. (2003). The Classification of Race, Ethnicity, Color, or National Origin (CRECNO) Initiative:A Guide to the Projected Impacts on Californians. eScholarship (California Digital Library). 1 indexed citations
10.
Rosenstein, Elliot D., et al.. (1996). Exacerbation of rheumatoid arthritis after termination of chemotherapy for breast carcinoma.. PubMed. 23(11). 1988–90. 7 indexed citations
11.
Kemeny, Nancy E., Donna Niedzwiecki, Bonnie Reichman, et al.. (1989). Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma. Differences in survival in two patient groups with similar response rates. Cancer. 63(6). 1065–1069. 11 indexed citations
12.
Casper, E. S., et al.. (1985). Phase II trial of gallium nitrate in patients with advanced malignant melanoma.. PubMed. 69(9). 1019–20. 12 indexed citations
13.
14.
Michaelson, Richard A., et al.. (1983). Preoperative chemotherapy and radiation therapy in the management of anal epidermoid carcinoma. Cancer. 51(3). 390–395. 84 indexed citations
15.
Ahmed, Tamjeed, et al.. (1983). Phase II trial of bisantrene in advanced colorectal carcinoma.. PubMed. 67(3). 307–8. 1 indexed citations
16.
Michaelson, Richard A., George S. Benson, & Harvey M. Friedman. (1983). Urinary retention as the presenting symptom of acquired cytomegalovirus infection. The American Journal of Medicine. 74(3). 526–528. 7 indexed citations
17.
Michaelson, Richard A., N. E. Kemeny, & Charles W. Young. (1982). Phase II evaluation of 4'-epi-doxorubicin in patients with advanced colorectal carcinoma.. PubMed. 66(9). 1757–8. 8 indexed citations
18.
Michaelson, Richard A., et al.. (1980). Inhibition of the hypoprothrombinemic effect of warfarin (Coumadin) by Ensure Plus, a dietary supplement.. PubMed. 10(4). 171–2. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tatsunori Shimoi Breakdown of academic impact, for papers by Robert N. Raju Breakdown of academic impact, for papers by Devika Gajria Breakdown of academic impact, for papers by Rebecca Moroose Breakdown of academic impact, for papers by Hubert Orfeuvre Breakdown of academic impact, for papers by Mayra Ramos Breakdown of academic impact, for papers by Kaori Fujimoto-Ouchi Breakdown of academic impact, for papers by Virpi Rantanen Breakdown of academic impact, for papers by M. Wolf Breakdown of academic impact, for papers by Sylvie Assadourian
Rankless by CCL
2026